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Purpose
Active cellular therapy (ACT) using ex-vivo expanded
T cells from patients with cancer, obtained by apheresis,
can represent a viable source for anti-cancer directed
cellular therapy. TAAs expressed in glioblastoma may
represent attractive targets for i) CARS, ii) transgenic
T cells targeting nominal tumor antigens (e.g. NY-ESO-1)
or iii) T cells enriched for TAA after ex vivo expansion.
Methods
Fresh blood samples were obtained from 50 patients with
tumors of the central nervous system and tested for anti-
TAA reactivity. T cells were expanded without cytokines,
with IL-2 and IL-7, or with IL-2, IL-15 and IL-21 and
tested for CD4/8 expansion by flow cytometry and for
IFN-gamma production by ELISA. PBMCs were expanded
using IL-2/15/21 and peptides (15mers) covering TAAs
(surviving or NY-ESO-1). The T cell phenotype (CD3,
CD4, CD8, CD45RA and CCR7) was determined by flow
cytometry and TAA-reactive T cells were identified by
intracellular cytokine staining (IL-2, TNF, IFN and IL-17).
TAA-specific IgG in serum was detected by a quantitative
ELISA in patients with glioblastoma and in age- and sex-
matched healthy donors. FGFRvIII was determined by
RT-PCR and protein expression of survivin and NY-ESO-1
was evaluated by immunohistochemistry and graded using
a scale from 1+ to 4+ along with pattern analysis of TAA
expression.
Results
We could detect IFN-gamma responses in 25% blood
samples for NY-ESO-1 and 30% for survivin and anti-
gen-specific CD8 / CD4+ T cell proliferation. Cellular
responses could be augmented by adding cytokines,
i.e. IL-2 and IL-7 favored CD4+ T cell proliferation,
IL-2, IL-15 and IL-21 favored CD8+ T cell proliferation.
TAAs-reactive T cells could be successfully expanded ex
vivo and exhibited TAA-specific production of IFN-
gamma and TNFalpha and a CD8+CD45RA-CCR7+
phenotype. 38/50 specimens expressed NY-ESO-1, yet
only 3/50 showed a strong, universal (4+) NY-ESO-1
protein expression pattern, 12/50 cancer lesions exhib-
ited a strong (4+) staining for survivin defined by immu-
nohistochemistry. 25 % of glioblastoma tested positive
for the FGFRvIII.
Conclusion
A TAA-specific WBA (whole blood assay) can be used to
gauge the potential for expansion of TAA-reactive T cells
in peripheral blood from patients with glioblastoma. TAA-
reactive T cells can be successfully expanded from patients
with glioblastoma in IL-2, IL-15 and IL-21, they exhibit a
central memory phenotype and produce a Th1 cytokine
cytokine pattern. NY-ESO-1 expression in glioblastoma
represents a viable target for anti-NY-ESO-1 directed
T cells.
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